Details for New Drug Application (NDA): 020727

✉ Email this page to a colleague

NDA 020727 describes BIDIL, which is a drug marketed by Azurity and is included in one NDA. It is available from three suppliers. Additional details are available on the BIDIL profile page.

The generic ingredient in BIDIL is hydralazine hydrochloride; isosorbide dinitrate. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the hydralazine hydrochloride; isosorbide dinitrate profile page.

Summary for 020727

Tradename:	BIDIL
Applicant:	Azurity
Ingredient:	hydralazine hydrochloride; isosorbide dinitrate
Patents:	0

Pharmacology for NDA: 020727

Physiological Effect	Arteriolar Vasodilation Vasodilation

Suppliers and Packaging for NDA: 020727

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
BIDIL	hydralazine hydrochloride; isosorbide dinitrate	TABLET;ORAL	020727	NDA	Azurity	24338-010	24338-010-09	90 TABLET, FILM COATED in 1 BOTTLE (24338-010-09)
BIDIL	hydralazine hydrochloride; isosorbide dinitrate	TABLET;ORAL	020727	NDA AUTHORIZED GENERIC	Wilshire Pharmaceuticals	52536-006	52536-006-09	90 TABLET, FILM COATED in 1 BOTTLE (52536-006-09)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	37.5MG;20MG
Approval Date:	Jun 23, 2005	TE:	AB	RLD:	Yes

Expired US Patents for NDA 020727

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	BIDIL	hydralazine hydrochloride; isosorbide dinitrate	TABLET;ORAL	020727-001	Jun 23, 2005	⤷ Get Started Free	⤷ Get Started Free
Azurity	BIDIL	hydralazine hydrochloride; isosorbide dinitrate	TABLET;ORAL	020727-001	Jun 23, 2005	⤷ Get Started Free	⤷ Get Started Free
Azurity	BIDIL	hydralazine hydrochloride; isosorbide dinitrate	TABLET;ORAL	020727-001	Jun 23, 2005	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.